Acosta: Study on anti-dengue vaccine affirms PAO’s probe
A RECENT study by international doctors about the effects of an anti-dengue vaccine on recipients who have not yet been affected by the disease agrees with the claims of the Public Attorney’s Office (PAO) against Dengvaxia.
This was the assertion of PAO chief Atty. Persida Acosta, as she cited the study posted on the website of New England Journal of Medicine (NEJM) yesterday.
“I have not read that, ngayon ko lang nalaman ‘yan, at nagpapasalamat po ako na meron palang mga doktor na talagang tumutulong,” Acosta said.
NEJM said in its original article titled “Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy” that dengue “seropositive patients,” or those who were infected with the dengue virus prior to the immunization of the anti-dengue vaccine, had protection of at least five years.
However, the same study noted, the rates of hospitalization for dengue infection and severe dengue went high among “seronegative patients,” or those who were not infected prior to vaccination.
“Our findings support the hypothesis that, in the absence of previous dengue exposure, the dengue vaccine partially mimics primary infection and increases the risk of severe dengue during subsequent infection,” NEJM said.—